For many people with psoriasis, treatment starts on the surface. Creams and ointments can help calm inflamed skin and often work well when plaques are mild or limited to small areas.
But plaques can spread to larger areas or settle into hard-to-treat spots, like your scalp, nails, or genitals. At that point, rubbing on medicine once or twice a day can be hard to keep up with. And for some people, topicals just don’t cut it.
That’s when doctors turn to treatments that work throughout the body. Some already come as pills. Others are injectable medicines called biologics. These shots work very well for psoriasis, but doctors know they’re not a good fit for everyone, especially those who prefer not to use injections.
For years, researchers have been chasing a tough goal: a pill that works on the same powerful pathways as biologics without bringing new side effects or safety concerns. That search led to icotrokinra (Icotyde), a once-daily oral drug designed to target the immune signal that drives psoriasis.
Step 1: The Science Behind Icotrokinra
Psoriasis isn’t just a skin problem. It starts deeper, in the immune system, when certain signals stay switched on for too long. One of the most important is an inflammatory protein called interleukin-23, or IL-23.
IL-23 is made by immune cells that help the body respond to threats, like infections or injury. In healthy skin, it helps start inflammation then quiets once healing begins. When that shutoff fails, skin cells grow too fast and don’t shed the way they should.
When scientists discovered that people with plaque psoriasis tend to have high levels of IL-23 in their skin, especially in active plaques, it changed how they thought about treatment. Instead of focusing on only calming symptoms, researchers began targeting the driving force behind the disease.
Doctors already use injectable medicines that block IL-23, or closely related immune signals, to manage psoriasis. These treatments showed that interrupting this pathway can lead to major skin improvement. They also confirmed IL-23’s central role in the disease.
That success raised the next question: Could we target the same pathway with a pill instead of a shot?
Icotrokinra was designed to help answer that question. It’s a once-daily pill that blocks the IL-23 receptor, which is the spot where IL-23 delivers its message. By blocking that site, the drug helps shut down the signals that keep psoriasis-related inflammation going.
The goal wasn’t to reinvent psoriasis care, but to build on what already works. By targeting the same immune pathway as highly effective biologics in pill form, researchers aimed to offer another choice — one that may fit more easily into everyday life.
Step 2: Early Testing
Before testing icotrokinra in people, researchers studied it in the lab. They needed to confirm that the drug blocked the IL-23 signal as planned and that it could be taken as a pill and absorbed reliably by the body.
Next, they tested icotrokinra in animals to look for early safety signals. These studies helped answer important questions about dosing and side effects and whether the drug could calm psoriasis-related inflammation without causing harm.
After icotrokinra cleared these early steps, it moved into human studies.
Step 3: Testing in People
Once icotrokinra showed promise in early lab and animal studies, researchers moved into clinical trials. These studies test new treatments in people and are done in phases, with each step designed to answer a different question before moving forward.
Phase 1 and phase 2: Is it safe, and does it work?
In early studies, researchers tested icotrokinra in small groups of adults to learn how the body absorbs the drug and to look for early safety issues. These studies offered the first signs that blocking the IL-23 pathway with a pill could treat psoriasis-related inflammation.
Phase 2 studies then included more people with plaque psoriasis. Researchers focused on finding the right dose and confirming that the drug could improve skin symptoms without causing a lot of side effects or safety concerns.
Phase 3: Larger trials with more people
Phase 3 trials are the final step before a company can ask the FDA to approve a drug. These studies are larger, last longer, and are designed to show clearly how well a treatment works compared with existing options.
The main phase 3 studies for icotrokinra were called ICONIC-ADVANCE 1 and 2. Researchers enrolled hundreds of people ages 12 and older with moderate-to-severe plaque psoriasis.
To take part, participants had to:
- Have plaque psoriasis for at least six months
- Have psoriasis covering about 10% or more of their body
- Be candidates for light therapy or other whole-body treatments
People with non-plaque forms of psoriasis weren’t included.
How the studies worked. In the ICONIC trials, participants were randomly assigned to take one of these:
- Icotrokinra once a day
- A placebo (a pill with no active drug)
- Deucravacitinib, the most effective oral psoriasis treatment
The studies were double-blind, which means neither the participant nor the researcher knew who was getting which treatment. This adds reliability and trust to the trial results.
What the results showed. Across phase 3 trials, people taking icotrokinra had clearer skin and better symptom relief than those taking placebo or deucravacitinib.
After 16 weeks (about four months):
- About 7 out of 10 people taking icotrokinra had skin that was clear or almost clear
- About half had skin that was 90% clearer than when they started
- About 1 in 3 had completely clear skin
The studies also looked at what participants reported about their symptoms and quality of life. That helps show whether improvements are meaningful to people. Psoriasis affects many parts of daily life, so doctors want to see both skin improvement and real gains in how people feel and function from day to day.
What about side effects? They were generally mild. The most common were:
- Colds
- Sore throats
- Upper respiratory infections
Serious side effects were uncommon, and safety stayed steady over time.
Step 4: Checking by Experts
Based on phase 3 results, Johnson & Johnson submitted a New Drug Application seeking the first FDA approval of icotrokinra for adults and adolescents with moderate-to-severe plaque psoriasis.
While strong clinical trial results are an important marker, they don’t send a drug straight to the pharmacy. Before that can happen, the data goes to the Center for Drug Evaluation and Research (CDER). The CDER is a group within the FDA that reviews new medicines.
Teams at the CDER, including doctors, scientists, and other specialists, take a close look at years of research. They review clinical trial results, safety data, and details about how the drug is made and how it would be labeled if approved.
Step 5: Watching Over Time
After a drug is approved, doctors and researchers continue to watch how it works in real-world use. This ongoing follow-up helps catch side effects that may not show up during clinical trials. This is called postmarketing surveillance.
Even large studies can’t uncover every possible issue. That’s why doctors report any new safety concerns as they arise and why it’s important to mention any side effects you notice. The FDA can update safety guidance or prescribing information if needed.
This kind of monitoring helps confirm that a treatment stays safe and effective outside of research studies, which matters because many people use psoriasis treatment for years.
Should You Try Icotronkinra?
It may be worth discussing if you have moderate-to-severe plaque psoriasis, especially if topical treatments aren’t enough or if you’d prefer a pill over shots or infusions. Even if icotrokinra isn’t the right fit, you should still talk with your doctor about all your choices. Psoriasis care has advanced a lot in recent years. There may be more effective treatments available than you realize. Your dermatologist can help you decide what makes the most sense for your situation.
Related Links 
